A Phase 2, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), and Palivizumab When Administered in the Same Season

Trial Profile

A Phase 2, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), and Palivizumab When Administered in the Same Season

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2012

At a glance

  • Drugs Motavizumab (Primary) ; Palivizumab (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions
  • Sponsors MedImmune
  • Most Recent Events

    • 27 Apr 2010 Actual end date (Apr 2007) added as reported by ClinicalTrials.gov.
    • 16 Oct 2009 Results will be presented at the American Academy of Pediatrics (AAP) 2009 National Conference and Exhibition, according to a MedImmune media release.
    • 27 Aug 2007 The expected completion date for this trial is now 1 Feb 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top